Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.

2007799 citationsReview

Authors

Curt D. Furberg · Wake Forest University

Abstract

Among patients with impaired glucose tolerance or type 2 diabetes, rosiglitazone use for at least 12 months is associated with a significantly increased risk of myocardial infarction and heart failure, without a significantly increased risk of cardiovascular mortality.

Topics & Keywords

Diabetes Treatment and Management Peroxisome Proliferator-Activated Receptors Metabolism, Diabetes, and Cancer

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: PubMed

Volume 298, Issue 10, pp. 1189-95

DOI: 10.1001/jama.298.10.1189

Field-Weighted Citation Impact: 67.89